With this acquisition, Hikma intends to strengthen its API sourcing and R&D capabilities in key product areas.
The deal allows Hikma to get license to Haosun’s APIs particularly targeting oncology area.
Haosun is engaged in organic synthesis, fermentation production, process development and manufacturing.